Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYH2046
- Development stage
- Unknown
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SYH2046 is an orally administered small molecule therapeutic being developed by Shanghai Yishi Pharmaceutical Technology (上海翊石医药科技有限公司) for the treatment of heart failure, specifically in patients following an acute myocardial infarction. The drug is currently undergoing Phase 1 clinical evaluation in China to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and heart failure patients. While the specific biological target has not been widely disclosed in public literature, the program is positioned within Yishi Pharma's cardiovascular pipeline, focusing on improving cardiac function and outcomes post-ischemic injury.
Beyond the preview
Go deeper on SYH2046.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYH2046.